Current Agents Approved for Treatment of HCC
Ghassan Abou-Alfa, MD, discusses the approved agents available for the treatment of hepatocellular carcinoma. Compared to 2007 when there was only 1 agent available, sorafenib, there is now a great number of options for these patients.
Ghassan Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the approved agents available for the treatment of hepatocellular carcinoma (HCC). Compared to 2007 when there was only 1 agent available, sorafenib (Nexavar), there is now a great number of options for these patients.
In the frontline setting, lenvatinib (Lenvima) is approved. In the second-line, regorafenib (Stivarga) is approved for use after patients have progressed on sorafenib. There is also a conditional approval for nivolumab (Opdivo) in the second-line setting of HCC.
Encouraging data is available for cabozantinib (Cabometyx) in the second- and third-line settings, as well as ramucirumab (Cyramza) in the second-line for patients with high alpha-fetoprotein.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
